Table 3. Open in new tab LV function in...

Table 3.

LV function in patients who had persistent cardiotoxicity after trastuzumab completion or discontinuation.

ID	Age	Baseline GLS	Nadir GLS	GLS at final follow-up	Baseline LVEF	Nadir LVEF	LVEF at final follow-up	Worst NYHA	Follow-up (days)	Pre-existing cardio-myopathy	Discontinued trastuzumab prematurely due to cDLT
16	62	−21.8	−15	−16.9	58	50	51	I	155	No	No
23	65	−17.8	−6.8	−12.9	58	26	58	III	1416	No	Yes
28	68	−20.2	−14.1	−14.9	58	50	53	I	602	No	No
37	41	N/A	−12.4	−16.6	58	45	47	II	759	No	No
38	64	−21.8	11.5	−16.7	61	38	53	I	974	No	No
39	69	N/A	−14.1	−14.2	60	45	49	I	155	No	No
43	65	−22.6	−16.9	−16.9	67	45	56	II	256	No	Yes

ID	Age	Baseline GLS	Nadir GLS	GLS at final follow-up	Baseline LVEF	Nadir LVEF	LVEF at final follow-up	Worst NYHA	Follow-up (days)	Pre-existing cardio-myopathy	Discontinued trastuzumab prematurely due to cDLT
16	62	−21.8	−15	−16.9	58	50	51	I	155	No	No
23	65	−17.8	−6.8	−12.9	58	26	58	III	1416	No	Yes
28	68	−20.2	−14.1	−14.9	58	50	53	I	602	No	No
37	41	N/A	−12.4	−16.6	58	45	47	II	759	No	No
38	64	−21.8	11.5	−16.7	61	38	53	I	974	No	No
39	69	N/A	−14.1	−14.2	60	45	49	I	155	No	No
43	65	−22.6	−16.9	−16.9	67	45	56	II	256	No	Yes